Ricardo Signs Deal to Support Singer With Bespoke Manual Transmissions
13.2.2025 11:00:00 EET | Business Wire | Press release
Ricardo, a global strategic, environmental, and engineering consulting company, has signed a deal to supply bespoke, manual transmissions to Singer’s operations in the US and UK.
The transmissions will be exclusive to Singer and will initially be available to owners who request Singer’s Classic Turbo or DLS Turbo restoration services for their Type 964 Porsche 911.
Singer arrived on the automotive scene with their Classic services in 2009. Since then, the company has developed restoration services allowing owners to personalise both naturally aspirated and turbocharged cars. A Porsche 911 Reimagined by Singer is a rare machine, bringing together iconic design with twenty-first century engineering and material science.
Ricardo’s design team will ensure that the transmissions meets the exacting, high performance needs of Singer’s clients. The focus is on delivering an H-pattern transmission able to accommodate the additional demands that a turbocharged car places on the drivetrain. Designed to seamlessly integrate into the existing chassis, the transmission will enable smooth, engaging gear shift operations despite the increased torque and power demands.
The transmissions will be manufactured and tested at Ricardo’s state of the art Midlands Technical Centre in Leamington Spa, UK.
Richard Guest, Managing Director of Performance Products at Ricardo, said: “We are delighted to be working on this significant multi-year project, supplying Singer in the UK and US with a series of transmissions that will support the growth of their customer base. The passion and detail that they demonstrate through these vehicles is a great match with the drivetrain expertise that Ricardo can provide. We look forward to supporting the Singer team on this project and building on our existing relationship.”
Mazen Fawaz, Chief Strategy Officer, Singer Group, notes: “Our approach is always based around execution without compromise. This leads us to seek out and collaborate with the best in the world. An exceptional, truly engaging, manual transmission is an essential part of the remarkable sports cars that we pursue, on behalf of some of the most discerning drivers in the world. We look forward to continuing this pursuit in collaboration with Ricardo.”
About Ricardo
Ricardo plc is a global strategic, environmental, and engineering consulting company, listed on the London Stock Exchange. With over 100 years of engineering excellence and employing close to 3,000 employees in more than 20 countries, we provide exceptional levels of expertise in delivering innovative cross-sector sustainable outcomes to support energy transition, environmental services together with safe and smart transport. Our global team of consultants, environmental specialists, engineers and scientists support our customers to solve the most complex and dynamic challenges to help achieve a safe and sustainable world. Visit www.ricardo.com
About Singer
Founded in California in 2009, Singer represents a philosophy simply expressed as A Relentless Pursuit of Excellence.
The company has become renowned for its collaboration with owners of the air-cooled Porsche 911 to reimagine bespoke restorations. Singer’s philosophy embodies:
- A highly personalized approach and exquisite execution
- A passionate focus on iconic design and a homage to the world’s most iconic sportscars.
- Modern engineering and material science combined with jewel-like details.
- A deep connection with California and its automotive zeitgeist.
Visit www.singervehicledesign.com
Singer is not sponsored, associated, approved, endorsed nor, in any way, affiliated with Porsche Cars North America, Inc., or Dr. Ing. h.c. F. Porsche, AG. Dr. Ing. h.c. F. Porsche AG is the owner of numerous trademarks, both registered and unregistered, including, without limitation, the Porsche Crest®, Porsche®, and the model numbers and names and the distinctive shapes of the Porsche automobiles, such as the federally registered 911 automobile. Any mention of Porsche Cars North America, Inc., or Dr. Ing. h.c. F. Porsche, AG. trademarked names or other marks is for purpose of reference only.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250212195492/en/
Contacts
Media contact for Ricardo:
Rebecca Roper, Marketing Manager – Performance Products
Email: rebecca.roper@ricardo.com
Telephone: +44 1273 794609
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release
PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom